Document Detail


Pregnancy prolongation in triplet pregnancies. Oral vs. continuous subcutaneous terbutaline.
MedLine Citation:
PMID:  11762154     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess gestational gain in triplet pregnancies treated with oral terbutaline followed by treatment with continuous subcutaneous terbutaline. STUDY DESIGN: From a database of patients who received perinatal home care services, we identified women with triplet gestations first receiving daily oral terbutaline following an episode of threatened preterm labor who subsequently received continuous subcutaneous terbutaline infusion after recurrence of preterm contractions. The primary outcome studied was gestational gain with oral terbutaline vs. gestational gain with continuous subcutaneous terbutaline infusion. RESULTS: One hundred four women were studied. The mean gestational age at enrollment was 22.0 +/- 2.7 weeks. Significantly more gestational gain was achieved during subcutaneous tocolytic treatment than during oral treatment (mean 5.4 +/- 3.4 vs. 2.8 +/- 2.2 weeks, P < .001). Twenty-nine percent of desired prolongation was achieved with oral terbutaline, while 71% of desired prolongation was achieved with subcutaneous terbutaline infusion (P < .001). The mean gestational age at delivery was 33.2 +/- 2.2 weeks. CONCLUSION: Gestational gain was greater in triplet pregnancies during treatment with continuous subcutaneous terbutaline infusion than with oral terbutaline.
Authors:
J P Elliott; N K Bergauer; D L Jacques; S K Coleman; G J Stanziano
Related Documents :
8910784 - Selective reduction of pregnancy: a legal analysis.
1769814 - Birth of the first 100 babies in hawaii after conception in-vitro: experience at the pa...
8821024 - Multifetal pregnancy reduction and selective termination.
8106944 - A conservative treatment protocol with human menopausal gonadotropins aimed at reducing...
19342014 - Timing of oocyte maturation and egg collection during controlled ovarian stimulation: a...
12743674 - Efficacy, safety and cost of new drugs acting on the central nervous system.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  The Journal of reproductive medicine     Volume:  46     ISSN:  0024-7758     ISO Abbreviation:  J Reprod Med     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-12-12     Completed Date:  2002-03-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0173343     Medline TA:  J Reprod Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  975-82     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Good Samaritan Medical Center, Phoenix, Arizona, USA. john_elliott@obstetrix.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Female
Gestational Age
Humans
Infusions, Intravenous
Obstetric Labor, Premature / prevention & control*
Perinatal Care
Pregnancy
Pregnancy Outcome
Retrospective Studies
Terbutaline / administration & dosage*,  therapeutic use
Time Factors
Tocolytic Agents / administration & dosage*,  therapeutic use
Triplets*
Chemical
Reg. No./Substance:
0/Tocolytic Agents; 23031-25-6/Terbutaline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Urinary profile of endogenous steroids in postmenopausal women with stress urinary incontinence.
Next Document:  Medical vs. Surgical treatment of ectopic pregnancy. The University of New Mexico's six-year experie...